Evidence map›Paper›PMID 29696219›Full record

ArticleContemporary clinical trials communications2018

Perceived barriers to pediatrician and family practitioner participation in pediatric clinical trials: Findings from the Clinical Trials Transformation Initiative.

Rachel G Greenberg, Amy Corneli, John Bradley, John Farley, Hasan S Jafri, Li Lin, Sumathi Nambiar, Gary J Noel, Chris Wheeler, Rosemary Tiernan and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Contemporary clinical trials communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Rachel G GreenbergDuke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27705, USA.
Amy CorneliDuke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27705, USA.
John BradleyRady Children's Hospital, University of California San Diego, 3020 Children's Way, San Diego, CA 92123, USA.
John FarleyFood and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA.
Hasan S JafriMedImmune, 1 Medimmune Way, Gaithersburg, MD 20878, USA.
Li LinDuke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27705, USA.
Sumathi NambiarFood and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA.
Gary J NoelJohnson & Johnson, 1003 US-202, Raritan, NJ 08869, USA.
Chris WheelerFood and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA.
Rosemary TiernanFood and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA.
P Brian SmithDuke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27705, USA.
Jamie RobertsClinical Trials Transformation Initiative, 300 W. Morgan Street, Suite 800, Durham, NC 27701, USA.
Daniel K BenjaminDuke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27705, USA.

Funding

FDA HHS R18 FD005292FDA HHS U18 FD005292
6 · The paper itself

Abstract

Despite legislation to stimulate pediatric drug development through clinical trials, enrolling children in trials continues to be challenging. Non-investigator (those who have never served as a clinical trial investigator) providers are essential to recruitment of pediatric patients, but little is known regarding the specific barriers that limit pediatric providers from participating in and referring their patients to clinical trials. We conducted an online survey of pediatric providers from a wide variety of practice types across the United States to evaluate their attitudes and awareness of pediatric clinical trials. Using a 4-point Likert scale, providers described their perception of potential barriers to their practice serving as a site for pediatric clinical trials. Of the 136 providers surveyed, 52/136 (38%) had previously referred a pediatric patient to a trial, and only 17/136 (12%) had ever been an investigator for a pediatric trial. Lack of awareness of existing pediatric trials was a major barrier to patient referral by providers, in addition to consideration of trial risks, distance to the site, and time needed to discuss trial participation with parents. Overall, providers perceived greater challenges related to parental concerns and parent or child logistical barriers than study implementation and ethics or regulatory barriers as barriers to their practice serving as a trial site. Providers who had previously been an investigator for a pediatric trial were less likely to be concerned with potential barriers than non-investigators. Understanding the barriers that limit pediatric providers from collaboration or inhibit their participation is key to designing effective interventions to optimize pediatric trial participation.

Indexed as

AAP, American Academy of PediatricsABDDABDD, antibacterial drug developmentCTTI, Clinical Trials Transformation InitiativeEnrollmentFDA, Food and Drug AdministrationNIH, National Institutes of HealthPediatric clinical trialsPeds ABDD, Clinical Trials Transformation Initiative Pediatric Trials in Antibacterial Drug DevelopmentPractitioner referralProvider referralUS, United States

Identifiers

PMID29696219
PMCPMC5898553

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.